BELTSVILLE, Md. & SAN DIEGO--(BUSINESS WIRE)--MetaMorphix, Inc. (MMI) and Sequenom, Inc. (NASDAQ:SQNM) today announced the strengthening of their partnership through MMI’s adoption of Sequenom’s MassARRAY® and iPLEX™ foundation technologies, which provide cost-effective genotyping and enhanced efficiencies.
